实现只需一剂即可治愈溃疡分枝杆菌感染的目标。
Toward a Single-Dose Cure for Buruli Ulcer.
机构信息
NTU Institute for Health Technologies (HealthTech NTU), Interdisciplinary Graduate Programme, Nanyang Technological University, Singapore.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
出版信息
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00727-20.
Abstract
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
摘要
在感染了布鲁里溃疡的小鼠模型中，单次给予 Q203（结核病的 2 期临床候选药物）即可彻底消除感染，且在治疗后 19 周内无复发。Q203 的临床应用可能会极大地简化对布鲁里溃疡这种被忽视的分枝杆菌病的临床管理。
相似文献
1
Toward a Single-Dose Cure for Buruli Ulcer.
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00727-20.
2
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00426-19. Print 2019 Jul.
3
Targeting the Mycobacterium ulcerans cytochrome bc:aa for the treatment of Buruli ulcer.
Nat Commun. 2018 Dec 18;9(1):5370. doi: 10.1038/s41467-018-07804-8.
4
Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0141821. doi: 10.1128/AAC.01418-21. Epub 2021 Aug 30.
5
Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease.
Chimia (Aarau). 2023 Sep 20;77(9):577-581. doi: 10.2533/chimia.2023.577.
6
Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00259-20.
7
Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.
PLoS Negl Trop Dis. 2020 Aug 31;14(8):e0007857. doi: 10.1371/journal.pntd.0007857. eCollection 2020 Aug.
8
Determination of Bioenergetic Parameters in Mycobacterium ulcerans.
Methods Mol Biol. 2022;2387:219-230. doi: 10.1007/978-1-0716-1779-3_21.
9
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.
EMBO Mol Med. 2021 Jan 11;13(1):e13207. doi: 10.15252/emmm.202013207. Epub 2020 Dec 7.
10
Unlocking Opportunities for and .
ACS Infect Dis. 2024 Feb 9;10(2):251-269. doi: 10.1021/acsinfecdis.3c00371. Epub 2024 Jan 31.
引用本文的文献
1
A Review of Antibacterial Candidates with New Modes of Action.
ACS Infect Dis. 2024 Oct 11;10(10):3440-3474. doi: 10.1021/acsinfecdis.4c00218. Epub 2024 Jul 17.
2
Unlocking Opportunities for and .
ACS Infect Dis. 2024 Feb 9;10(2):251-269. doi: 10.1021/acsinfecdis.3c00371. Epub 2024 Jan 31.
3
Recent Advances in the Management Strategies for Buruli Ulcers.
Pathogens. 2023 Aug 27;12(9):1088. doi: 10.3390/pathogens12091088.
4
Antibiotics in the clinical pipeline as of December 2022.
J Antibiot (Tokyo). 2023 Aug;76(8):431-473. doi: 10.1038/s41429-023-00629-8. Epub 2023 Jun 8.
5
Sensitivity of Mycobacterium leprae to Telacebec.
Emerg Infect Dis. 2022 Mar;28(3):749-751. doi: 10.3201/eid2803.210394.
6
Overview: Development of Drugs Against Mycobacterium ulcerans.
Methods Mol Biol. 2022;2387:185-187. doi: 10.1007/978-1-0716-1779-3_17.
7
Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0141821. doi: 10.1128/AAC.01418-21. Epub 2021 Aug 30.
8
In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera.
PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009636. doi: 10.1371/journal.pntd.0009636. eCollection 2021 Jul.
本文引用的文献
1
Telacebec (Q203), a New Antituberculosis Agent.
N Engl J Med. 2020 Mar 26;382(13):1280-1281. doi: 10.1056/NEJMc1913327.
2
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
Lancet. 2020 Apr 18;395(10232):1259-1267. doi: 10.1016/S0140-6736(20)30047-7. Epub 2020 Mar 12.
3
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00426-19. Print 2019 Jul.
4
Targeting the Mycobacterium ulcerans cytochrome bc:aa for the treatment of Buruli ulcer.
Nat Commun. 2018 Dec 18;9(1):5370. doi: 10.1038/s41467-018-07804-8.
5
Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.
Clin Microbiol Rev. 2017 Dec 13;31(1). doi: 10.1128/CMR.00045-17. Print 2018 Jan.
6
Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia.
Emerg Infect Dis. 2018 Jan;24(1):58-64. doi: 10.3201/eid2401.171070. Epub 2018 Jan 17.
7
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
PLoS Negl Trop Dis. 2016 Oct 18;10(10):e0005066. doi: 10.1371/journal.pntd.0005066. eCollection 2016 Oct.
8
Burden of Mycobacterium ulcerans disease (Buruli ulcer) and the underreporting ratio in the territory of Songololo, Democratic Republic of Congo.
PLoS Negl Trop Dis. 2013 Dec 5;7(12):e2563. doi: 10.1371/journal.pntd.0002563. eCollection 2013.
9
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
Nat Med. 2013 Sep;19(9):1157-60. doi: 10.1038/nm.3262. Epub 2013 Aug 4.
10
Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Antimicrob Agents Chemother. 2012 Feb;56(2):687-96. doi: 10.1128/AAC.05543-11. Epub 2011 Dec 5.
Zotero 插件